Trials / Completed
CompletedNCT00328497
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single center, open-label study will evaluate the safety and efficacy of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant human monoclonal antibody against vascular endothelial growth factor (bevacizumab) administered intravenously, in patients with locally advanced or metastatic carcinoid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-12-01
- Completion
- 2009-12-01
- First posted
- 2006-05-22
- Last updated
- 2010-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00328497. Inclusion in this directory is not an endorsement.